Vitiligo Treatment Market Share

North America Market Analysis

North America in vitiligo treatment market is likely to account for around 40.8% revenue share by 2037, owing to developed healthcare infrastructure, significant investment in research and development, and rising awareness levels. Increasing healthcare spending, coupled with the presence of key market players, is further propelling market growth.  The U.S. and Canada are projected to contribute the major share of the North America vitiligo treatment market.

The increasing prevalence of vitiligo in the United States, the emerging healthcare industry, the growing adoption of modern technologies, and rising innovative surgery procedures by key players are the factors driving the U.S. market throughout the forecast period. According to the American Academy of Dermatology (AAD), in June 2022, vitiligo affects around one in four persons in the U.S. This huge vitiligo patient pool, along with growing demand for enhanced therapeutic approaches, is driving up demand for the market in the region.

Canada is experiencing growth in the vitiligo treatment market due to advancements in treatment options, increasing awareness, and a supportive healthcare system. For instance, in October 2024, Incyte Biosciences Canada declared that Health Canada has approved a Notice of Compliance for OPZELURA (ruxolitinib (as ruxolitinib phosphate)) cream 1.5%, a non-steroidal topical JAK inhibitor, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and more whose disease is not effectively controlled with conventional topical prescription therapies or when those therapies are not advisable.

Asia Pacific Market Analysis

Asia Pacific is expected to experience significant growth during the forecast period due to rising awareness of skin disorders, increasing patient population, and growing healthcare expenditure. The countries in the Asia Pacific dealing with vitiligo have resulted in the demand for improved treatment alternatives for vitiligo. The rise in knowledge of vitiligo, as well as initiatives to minimalize related stigma, are encouraging more people to seek treatment in the Asia Pacific. Moreover, the rising prevalence of vitiligo and the increasing demand for cosmetic and dermatological treatments are important drivers.

The China vitiligo treatment market is witnessing prominent growth in the country owing to the ongoing research and development activities and innovations in the available treatments to cater to the rising vitiligo cases. In September 2023, Huahai Institute of Vitiligo Research expanded its operations in Shanghai, to bring TCM-based vitiligo treatment to local patients, thus, improving accessibility to high-caliber traditional Chinese medicines. Furthermore, in April 2024, China Medical System Holdings Limited and Incyte entered into a partnership and license agreement to develop and commercialize povorcitinib in Mainland China, Macao, Hong Kong, and Taiwan.

Japan has a significantly high demand for dermatological and cosmetic treatments. Also, the penetration of global players in the country has improved vitiligo treatments. In 2023, Merck initiated the clinical trial for MK-6194 in several countries including Japan, catering to non-segmental vitiligo patients.